Semax on TikTok: separating nootropic hype from real evidence

What did @stanmilsom1 actually say?

Stan gave a casual update on several weeks of inconsistent use of two Russian-origin peptides, semax and selank, both administered as nasal sprays. His main claim is that semax produces noticeable focus and productivity: "you'll just lock in and you'll just be down bang bang bang bang" for two to three hours of uninterrupted work. He also said selank hasn't done much for him in the evening, which he chalks up to already being tired. He's planning to switch both from nasal spray to subcutaneous injection because he prefers injecting and has an established injection routine with other peptides.

He's not making dramatic medical claims here. This is a personal anecdote with some protocol thinking layered on top. Still, the switch from nasal to injectable semax deserves scrutiny, and the focus claims are worth stress-testing against what research actually exists.

Does the science back this up?

Semax has a real, if limited, evidence base, mostly from Russian and Eastern European clinical research. The focus claim is the most plausible thing Stan said. Selank's sleep application has some logic behind it, but calling it unproven in Western clinical trials is an understatement.

Semax is a synthetic heptapeptide derived from ACTH(4-7). It has been shown to increase BDNF in rat models and has demonstrated neuroprotective effects in several small human trials conducted in Russia. Dolotov et al. (2006, Journal of Molecular Neuroscience) found semax increased BDNF expression in rodent brain tissue, which provides a plausible mechanism for cognitive effects. However, randomized controlled trials in healthy adults are essentially nonexistent in peer-reviewed Western literature. The "lock in" effect Stan describes is consistent with what anecdotal users report, but it has not been formally measured in controlled conditions.

Selank is an anxiolytic peptide that has been studied primarily for generalized anxiety disorder. Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) showed anxiolytic effects comparable to benzodiazepines in some animal models without sedative side effects. The calming and sleep-adjacent use Stan describes is biologically plausible, but again, human RCT data is thin.

What did they get wrong (or right)?

The biggest issue is the switch to injectable semax. Stan says "I just prefer pinning stuff" as his primary justification. That's a personal preference, not a pharmacological one, and it matters here because semax is specifically designed for intranasal delivery. The nasal route puts the peptide in proximity to the olfactory epithelium and allows for direct nose-to-brain transport, bypassing first-pass metabolism and the blood-brain barrier more efficiently than subcutaneous injection for this particular compound.

There is no published evidence that injectable semax produces equivalent or superior CNS effects compared to intranasal semax in humans. Switching delivery routes because you prefer needles is not an evidence-based decision and could mean he's paying for a less effective method. That's worth saying plainly.

What he got right: his observation that selank isn't doing much when he takes it while already exhausted is actually reasonable thinking. If the compound's primary mechanism is anxiolytic and stress-modulating, taking it when anxiety is already zero because you're half-asleep limits what you'd notice. His instinct to try it in the morning alongside semax is worth exploring, though he should do that research before stacking.

What should you actually know?

Semax and selank are not approved by the FDA for any indication. In the US and UK, they exist in a gray area, often sourced from compounding pharmacies or research chemical suppliers with variable quality control. Anyone considering these compounds needs to understand that the evidence base is real but narrow, and almost entirely from Russian clinical settings that do not meet the trial design standards required for FDA approval.

The cognitive enhancement framing that runs through Stan's video, and through most semax content on TikTok, runs well ahead of the science. That doesn't mean semax does nothing. It means that robust, blinded, placebo-controlled data in healthy adults essentially does not exist in indexed Western journals. Anecdotes, including Stan's, are not clinical evidence, even when they're consistent across hundreds of users.

The injection preference also raises a practical safety point. Switching peptides from their studied delivery route introduces unknowns around bioavailability and dosing. If you're sourcing these compounds outside a supervised telehealth context, nobody is checking your injection technique, your reconstitution method, or whether your product is what it says it is.

• Semax is an ACTH-derived peptide with preliminary evidence for BDNF upregulation and neuroprotection, not a proven cognitive enhancer in healthy adults.
• Selank has anxiolytic data in animal models and small human trials, primarily for anxiety disorders, not sleep optimization.
• Nasal delivery is the studied and clinically used route for both peptides. Switching to injection for preference reasons is not supported by comparative pharmacokinetic data.
• Neither compound is FDA-approved. Quality and purity of gray-market sources vary significantly.